Drug intelligence / Profile preview

omega-conotoxin GVIA

Development stage
Preclinical
Lead developer
University of Utah
Modality
Peptides
Administration
Experimental (typically In Vitro, Not Used In Humans), Routes In Animal Models Include Intrathecal, Intracerebral, Or Tissue Bath
01

Overview

**omega-conotoxin GVIA** is a 27-amino-acid peptide toxin derived from the venom of *Conus geographus*, a fish-hunting marine cone snail. It is a highly selective and potent antagonist of **N-type (CaV2.2) voltage-gated calcium channels**. By binding to these channels, it inhibits neurotransmitter release, especially in neuronal tissues, making it a valuable research tool in neurobiology and pain research. Unlike the clinically approved ω-conotoxin MVIIA (ziconotide), GVIA itself is primarily used for experimental and pharmacological studies and is not an approved therapeutic. Its mechanism of action is orthosteric blockade of neuronal N-type calcium channels, which are critical for synaptic transmission in the central and peripheral nervous system.

Other names
ω-conotoxin GVIACgTx-GVIAConus geographus toxin GVIA
02

Targets

CACNA1B (Voltage-dependent N-type calcium channel subunit alpha-1B)

Beyond the preview

Go deeper on omega-conotoxin GVIA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega-conotoxin GVIA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call